Luteolin inhibits CVB3 replication through inhibiting inflammation

Area of Science:

• Virology
• Immunology
• Pharmacology

Background:

• Coxsackievirus B3 (CVB3) causes significant inflammation-related diseases, including viral myocarditis and aseptic meningitis.
• Current therapeutic options for CVB3 infections are limited, with no approved vaccines or drugs available.
• Understanding the molecular mechanisms of CVB3 pathogenesis is crucial for developing effective interventions.

Purpose of the Study:

• To investigate the antiviral and anti-inflammatory effects of luteolin against Coxsackievirus B3 (CVB3) infection.
• To elucidate the molecular mechanisms underlying luteolin's inhibitory action on CVB3 replication and associated inflammation.

Main Methods:

• Dose-dependent assessment of viral progeny production, CVB3 RNA, and protein synthesis in luteolin-treated cells.
• Analysis of key inflammatory signaling pathways, including p38 MAPK, JNK MAPK phosphorylation, and NF-κB nuclear translocation.
• Quantification of inflammatory cytokine expression in CVB3-infected cells following luteolin treatment.

Main Results:

• Luteolin demonstrated a dose-dependent reduction in CVB3 viral progeny, RNA, and protein synthesis.
• Luteolin inhibited the phosphorylation of p38 MAPK and JNK MAPK signaling pathways.
• Luteolin suppressed NF-κB nuclear translocation, leading to attenuated inflammatory cytokine expression in infected cells.

Conclusions:

• Luteolin exhibits significant antiviral properties against CVB3 infection.
• The anti-CVB3 mechanism of luteolin involves the modulation of MAPK and NF-κB signaling pathways.
• Luteolin represents a promising therapeutic agent or supplement for managing CVB3-induced inflammation and diseases.